Relapsed And Refractory Multiple Myeloma Rrmm clinical trials

Explore recruiting relapsed and refractory multiple myeloma rrmm clinical trials.

Recruiting relapsed and refractory multiple myeloma rrmm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed And Refractory Multiple Myeloma Rrmm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

Belgium, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment And is not Responsive After Treatment.

Spain, Germany, Sweden, Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Germany, Spain, Italy, France, Netherlands, Belgium +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A PHASE 2, MULTI-COHORT, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BB2121 IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND IN SUBJECTS WITH CLINICAL HIGH-RISK MULTIPLE MYELOMA

Spain, France, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Relapsed And Refractory Multiple Myeloma Rrmm trials by city

Relapsed And Refractory Multiple Myeloma Rrmm in Toronto Relapsed And Refractory Multiple Myeloma Rrmm in Vancouver Relapsed And Refractory Multiple Myeloma Rrmm in Montreal Relapsed And Refractory Multiple Myeloma Rrmm in Calgary Relapsed And Refractory Multiple Myeloma Rrmm in Edmonton Relapsed And Refractory Multiple Myeloma Rrmm in Ottawa Relapsed And Refractory Multiple Myeloma Rrmm in Winnipeg Relapsed And Refractory Multiple Myeloma Rrmm in Quebec City Relapsed And Refractory Multiple Myeloma Rrmm in Hamilton Relapsed And Refractory Multiple Myeloma Rrmm in Kitchener Relapsed And Refractory Multiple Myeloma Rrmm in London Relapsed And Refractory Multiple Myeloma Rrmm in Halifax Relapsed And Refractory Multiple Myeloma Rrmm in New York Relapsed And Refractory Multiple Myeloma Rrmm in Los Angeles Relapsed And Refractory Multiple Myeloma Rrmm in Chicago Relapsed And Refractory Multiple Myeloma Rrmm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease